Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMSA101 + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMSA101 | IMSA-101|IMSA 101 | STING1 Agonist 19 | IMSA101 is a cyclic GMP-AMP analog that functions as a STING1 agonist, which potentially activates immune cells resulting in enhanced antigen presentation and anti-tumor immune response (NCI Drug Dictionary). | |
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04020185 | Phase Ib/II | IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Completed | USA | 0 |